Lupin receives approval from USFDA for Brexpiprazole Tablets
Brexpiprazole Tablets, 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, and 4 mg, (RLD Rexulti) had estimated annual sales of US $1,575 million in the US (IQVIA MAT December 2022)
Brexpiprazole Tablets, 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, and 4 mg, (RLD Rexulti) had estimated annual sales of US $1,575 million in the US (IQVIA MAT December 2022)
The Congress gathers the whole value chain of the pharmaceutical industry on June, 12-13, 2023 in Switzerland
According to IQVIA sales data for the 12-month period ending January 2023, the Compazine Tablets, 5 mg and 10 mg market achieved annual sales of approximately US $26.9 million
This loan is in addition to earlier announced CAD 25 million loan committed by the Province of Quebec
Expands robotics to 20+ specialities
A funding to expand operations and provide better patient care
Time to combine innovation, access and technology to deliver positive patient outcomes
IIT Kanpur pioneers ground-breaking gene therapy technology for Hereditary Eye Diseases
The Development Center with its state-of-the art laboratories and flexible pilot capacities is set to become Siegfried's global research and development hub for its Drug Products sites, strengthening the global network
Digital success is contingent on the way a company organizes itself around technology
Subscribe To Our Newsletter & Stay Updated